A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease

Trial Profile

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Cerliponase alfa (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 05 Sep 2017 According to a BioMarin Pharmaceutical media release, data will be presented at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017.
    • 01 Jun 2017 According to a BioMarin Pharmaceutical media release, the European Commission (EC) has granted marketing authorization for Brineura (cerliponase alfa), the first treatment approved in the European Union for the treatment of (CLN2). The MAA was based on this and another study.
    • 08 Sep 2016 Updated long-term data from this trial will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2016 Annual Meeting, according to a BioMarin Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top